Ensysce Biosciences Inc (NASDAQ:ENSC) — Market Cap & Net Worth
Market Cap & Net Worth: Ensysce Biosciences Inc (ENSC)
Ensysce Biosciences Inc (NASDAQ:ENSC) has a market capitalization of $3.90 Million ($3.90 Million) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29032 globally and #5879 in its home market, demonstrating a 9.88% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ensysce Biosciences Inc's stock price $0.28 by its total outstanding shares 15365530 (15.37 Million). Review ENSC current and long-term liabilities to assess the company's total debt and financial obligations.
Ensysce Biosciences Inc Market Cap History: 2018 to 2026
Ensysce Biosciences Inc's market capitalization history from 2018 to 2026. Data shows change from $36.21 Billion to $4.27 Million (-66.27% CAGR).
Index Memberships
Ensysce Biosciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.00% | #862 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #2728 of 3165 |
Weight: Ensysce Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ensysce Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ensysce Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.79x
Ensysce Biosciences Inc's market cap is 2.79 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $38.43 Billion | $1.76 Million | $1.48 Million | 21783.99x | 26027.71x |
| 2020 | $45.86 Billion | $3.93 Million | $56.77K | 11664.55x | 807746.72x |
| 2021 | $17.33 Billion | $3.53 Million | -$29.15 Million | 4908.34x | N/A |
| 2022 | $138.29 Million | $2.52 Million | -$24.96 Million | 54.80x | N/A |
| 2023 | $16.29 Million | $2.23 Million | -$10.61 Million | 7.30x | N/A |
| 2024 | $125.08 Million | $5.21 Million | -$7.99 Million | 24.01x | N/A |
| 2025 | $14.14 Million | $5.07 Million | -$10.18 Million | 2.79x | N/A |
Competitor Companies of ENSC by Market Capitalization
Companies near Ensysce Biosciences Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Ensysce Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Ensysce Biosciences Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Ensysce Biosciences Inc's market cap moved from $36.21 Billion to $ 4.27 Million, with a yearly change of -66.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.27 Million | -69.78% |
| 2025 | $14.14 Million | -88.70% |
| 2024 | $125.08 Million | +667.92% |
| 2023 | $16.29 Million | -88.22% |
| 2022 | $138.29 Million | -99.20% |
| 2021 | $17.33 Billion | -62.20% |
| 2020 | $45.86 Billion | +19.33% |
| 2019 | $38.43 Billion | +6.11% |
| 2018 | $36.21 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Ensysce Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.90 Million USD |
| MoneyControl | $3.90 Million USD |
| MarketWatch | $3.90 Million USD |
| marketcap.company | $3.90 Million USD |
| Reuters | $3.90 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ensysce Biosciences Inc
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR)… Read more